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ttp://dx.doi.org/10.1016/j.ajpath.2014.06.001Dysregulation of the complement system is increasingly recognized as a contributing factor in age-
related macular degeneration. Although the complement regulator CD46 is expressed ubiquitously in
humans, in mouse it was previously thought to be expressed only on spermatozoa. We detected CD46
mRNA and protein in the posterior ocular segment (neuronal retina, retinal pigment epithelium, and
choroid) of wild-type (WT) C57BL/6J mice. Cd46/ knockout mice exhibited increased levels of the
membrane attack complex and of vascular endothelial growth factor (VEGF) in the retina and choroid.
The Cd46/ mice were also more susceptible to laser-induced choroidal neovascularization (CNV). In
Cd46/ mice, 19% of laser spots were positive for CNV at day 2 after treatment, but no positive spots
were detected in WT mice. At day 3, 42% of laser spots were positive in Cd46/ mice, but only 11% in
WT mice. A fully developed CNV complex was noted in both Cd46/ and WT mice at day 7; however,
lesion size was signiﬁcantly (P < 0.05) increased in Cd46/ mice. Our ﬁndings provide evidence for
expression of CD46 in the mouse eye and a role for CD46 in protection against laser-induced CNV. We
propose that the Cd46/ mouse has a greater susceptibility to experimental CNV because of insufﬁ-
cient complement inhibition, which leads to increased membrane attack complex deposition and VEGF
expression. (Am J Pathol 2014, 184: 2537e2548; http://dx.doi.org/10.1016/j.ajpath.2014.06.001)Supported by grants from the Edward N. & Della L. Thome Memorial
Foundation, the Lions of Arkansas Foundation, and the Pat andWillardWalker
Eye Research CentereHarvey&Bernice Jones Eye Institute and byNIH grants
R01-AI041592 (J.P.A.), R01-GM099111 (J.P.A.), P20-RR016460 (Digital
Microscopy Core), P30-DK052574 (Morphology Core), and P30-AR048335
(Protein Production and Puriﬁcation Core FacilityeRheumatic Diseases Core
Center).
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Disclosures: None delcared.Age-related macular degeneration (AMD) is a leading
worldwide cause of central vision loss in individuals over
the age of 50.1e5 The prevalence of AMD is growing
because of increased longevity. The disease brings negative
changes in life style. AMD patients often cannot perform
daily tasks of living, such as reading or driving. Current
estimates are that it requires 575 to 733 million dollars
annually to treat AMD in the United States.5 Thus, AMD
profoundly affects the quality of life, creating a serious
social and public health problem.3,4
Two major clinical phenotypes of AMD are recognized:
nonexudative (dry type) and exudative (wet type). Wet AMD is
frequently associated with central blindness, and choroidal
neovascularization (CNV) is the hallmark of this type in
humans. Agents available for treating exudative AMD reduce
the rate of vision loss, but they do not reverse damage; further-
more, they are associatedwith a variety of ocular complications,
require repetitive administration, and are expensive.1e4stigative Pathology.
.AMD is a disease with numerous risk factors, and mul-
tiple pathological mechanisms have been reported.6e10 Ev-
idence accumulated during the past decade, primarily
through genetic studies, strongly indicates that the alterna-
tive pathway of the complement system plays an important
role in AMD pathogenesis in humans.3,11e15 Reports from
multiple investigators have established that the membrane
attack complex (MAC) C5b-9, formed as a result of
Lyzogubov et alalternative pathway complement engagement, participates in
mediating animal models of CNV.11,12,16e23 Complement
regulatory proteins control the complement cascades,24,25
and their deﬁciency has been reported to predispose to the
development of experimental CNV.18,20
CD46 [alias membrane cofactor protein (MCP)] is a widely
expressed transmembrane glycoprotein in primates that serves
as a complement regulatory protein26,27 and is present in the
normal human eye.28e31 It binds C3b and C4b and then serves
as a cofactor protein for the cleavage of these two substrates
by serine protease factor I. In rodents, however, CD46 expres-
sion has been ﬁrmly established only for the inner acrosomal
membrane of spermatozoa.32e34 Our goal in the present
study was to investigate whether CD46 is expressed in the
mouse eye. After this was unequivocally shown, we explored its
role in a murine model of laser-induced CNV.11,12,35,36
Materials and Methods
Animals
A mouse with homozygous deﬁciency of Cd46 (Cd46/) on
the C57BL/6J background was generated at the Washington
University School of Medicine in St. Louis. Standard targeting
techniques37 were used to replace complement control protein
repeat 1 (CCP 1) and almost all of the CCP 2a sequence of the
mouseCd46genewith theNeocassette. Southernblottingwith a
probe between CCP 2b and CCP 3was used to conﬁrm targeted
embryonic stem cells (129Sv origin; Washington University
Cancer Center). Positive embryonic stem-cell clones were
expanded and microinjected into blastocyst-stage embryos of
C57BL/6J mice. The embryos were next transferred into the
uterus of surrogate females. Germline transmission of the dis-
rupted Cd46 gene was noted in chimeric mice, and the resultant
heterozygotes were bred to produce three genotypes: homozy-
gous, heterozygous, and wild-type (WT) mice. The phenotype
was unaltered, and reproductive capacity was normal.
Homozygous knockout mice were subsequently back-
crossed into C57BL/6J for at least eight generations. Neo
primers were used to detect the targeted band, and CD46
primers (CD46 primer A: 50-ATGCCTGTGAACTACCA-
CGGCCATTTGAAG-30; CD46 primer B: 50-AACTTTAA-
TATAGCTCCAGTGCCAGTTGCA-30) were used to detect
the deleted sequences. Genotypes of mice were determined by
PCR analysis of tail-derivedDNA.Male homozygousCd46/
mice, 6 to 8 weeks of age, were used. Age- and sex-matched
C57BL/6J mice purchased from the Jackson Laboratory (Bar
Harbor, ME) served as a WT control.
Preparation of Polyclonal Anti-CD46 Antibody
Using cDNA prepared from C57BL/6J mouse testes as a
template, full-length murine CD46 was ampliﬁed using the
following oligos: 50-CGCGGATCCATGACGGCGGCGC-
CTCTTAT-30 and 50-ATAAGAATGCGGCCGCTCATCT-
TGCTGCAGATACATTTG-30. The resulting PCR fragment2538was ligated into the BamHI and NotI sites of pET28a(þ)-2, a
derivative generated in our laboratory of pET-28a(þ)
(Novagen; EMDMillipore, Billerica, MA). This plasmid was
then used as a template to generate murine CD46 CCPs 1 and
2 and murine CD46 CCPs 3 and 4 separately, using the
following oligos: 50-CGCGGATCCATGGATGCCTGTG-
AACTACC-30 and 50-ATAAGAATGCGGCCGCTTAT-
TCACAATGTGGGGGATAGC-30 for CCPs 1 and 2, and
50-CGCGGATCCATGAAGATTTATTGTTTACCACC-
TC-30 and 50-ATAAGAATGCGGCCGCTTATTTAAGA-
CATTTTGGGATAGAT-30 for CCPs 3 and 4. The resulting
PCR fragments were ligated into the BamHI and NotI sites
of pET28a(þ)-2. The recombinant proteins were expressed
and puriﬁed as described previously.38 Refolded CCP 1 and
2 and CCP 3 and 4 proteins were pooled and then puriﬁed
over a Superose 12 sizing column (GE Healthcare, Little
Chalfont, UK). Pooled proteins were injected into rabbits
for polyclonal antibody (Ab) generation (Harlan Labora-
tories, Indianapolis, IN).RT-PCR Analysis
Total RNA was extracted from the posterior segment of eyes
[ie, neuronal retina, retinal pigment epithelium (RPE), and
choroid] and testes of WT and Cd46/ mice for RT-PCR
using an RNeasy kit (Qiagen, Valencia, CA). Speciﬁc oligo-
nucleotide primers derived from the mouse Cd46 gene (Na-
tional Center for Biotechnology Information; http://www.ncbi.
nlm.nih.gov/nuccore/NM_010778; accession number NM_
010778) were synthesized at Integrated DNA Technologies
(Coralville, IA). RT-PCR was performed using the following
primers: mouse b-actin, 50-GGCTGTATTCCCCTCCATCG-
30 (forward) and 50-AGCCTGGATGGCTACGTACA-30
(reverse); mouse CD46, 50-ATGCCTGTGAACTACC-
ACGGCCATTTGAAG-30 (forward) and 50-TTTGCCAA-
ATGAAGGGTCTTG-30 (reverse). RT-PCR for CD46 and
b-actin transcripts was performed using 0.1 mg of total RNA as
template, with reagents purchased from Bio-Rad Laboratories
(Hercules, CA). PCR was performed using 27, 29, and 35
cycles. The negative control reactions included nuclease-free
water (Ambion; Life Technologies, Carlsbad, CA) instead of
the RNA and a reaction lacking reverse transcriptase.Western Blot Analysis
Tissues harvested from the neuronal retina, RPE, and
choroid of WT and Cd46/ mice were homogenized and
solubilized in ice-cold phosphate-buffered saline contain-
ing 1% protease inhibitors and 1% NP-40 (Sigma-Aldrich,
St. Louis, MO). Electrophoresis was performed on 12%
SDSepolyacrylamide gels with 20 mg of total protein
loaded in each lane. The separated proteins were trans-
ferred to polyvinylidene diﬂuoride membranes. The blots
were blocked with 5% bovine serum albumin overnight at
4C. A rabbit polyclonal IgG reactive with mouse C9ajp.amjpathol.org - The American Journal of Pathology
CD46 Protects against CNV in Mice(dilution 1:40,000) provided by Prof. Brian P. Morgan
(University of Wales College of Medicine, Cardiff, UK)
and a monoclonal IgG to b-actin (dilution 1:10,000;
Sigma-Aldrich) were used as the primary Abs. The blots
were treated separately with these Abs at room temperature
for 2 hours. The anti-C9 Ab recognizes neoepitopes on C9
in the MAC.16e18 Horseradish peroxidaseelabeled goat
anti-rabbit IgG and horseradish peroxidaseelabeled goat
anti-mouse IgG (both from Santa Cruz Biotechnology,
Dallas, TX) were used as the secondary Abs for C9 and b-
actin, respectively. Blots were developed using an
enhanced chemiluminescence Western blotting detection
system (Pierce SuperSignal West Femto; Thermo Fisher
Scientiﬁc, Waltham, MA), according to the manufacturer’s
recommendations. Quantiﬁcation of protein bands was
accomplished by analyzing the intensity of the bands using
ImageJ software version 1.46r (NIH, Bethesda, MD).
ELISA
For enzyme-linked immunosorbent assay (ELISA),
neuronal retina, RPE, and choroid tissues were harvested
from enucleated eyes of WT and Cd46/ mice. The tissue
sample was placed in 500 mL of lysis buffer and homoge-
nized on ice for 30 seconds; the lysate was then centrifuged
at 9  g for 10 minutes at 4C. Levels of VEGF protein in
the supernatant were determined using a mouse VEGF
ELISA kit (R&D Systems, Minneapolis, MN). The assay
was performed according to the manufacturer’s recom-
mendations. Samples were analyzed in duplicate.
Immunohistochemical Studies
Immunoperoxidase Staining
Mouse epididymis was cut in 8-mm sections using a CM
1850 cryostat (Leica Microsystems, Wetzlar, Germany).
Sections were ﬁxed with 95% ethanol and 5% glacial acetic
acid for 10 minutes at room temperature. The endogenous
peroxidases were blocked by H2O2 (1.5%) in methanol for
30 minutes at room temperature. Sections were treated with
avidin and biotin blocking solutions (Vector Laboratories,
Burlingame, CA) for 15 minutes each. Tissues were incu-
bated with blocking solution (10% goat serum, 10% mouse
serum, and 1% bovine serum albumin in phosphate-buffered
saline) for 60 minutes at room temperature. Rabbit anti-
mouse CD46 at 4.2 mg/mL in blocking solution was
added to stain the sections for 60 minutes at room temper-
ature. After three washes with phosphate-buffered saline,
sections were incubated with 1:200 dilution of biotinylated
goat anti-rabbit IgG (Jackson ImmunoResearch Labora-
tories, West Grove, PA) for 60 minutes at room temperature.
Sections were subsequently incubated with an avidinebiotin
peroxidase complex (ABC complex; Vector Laboratories)
for 60 minutes at room temperature. Tissue structures were
visualized with ImmPACT 3,30-diaminobenzidine substrate
(Vector Laboratories).The American Journal of Pathology - ajp.amjpathol.orgImmunoﬂuorescence Staining
Identiﬁcation and Localization of CD46 in Mouse Eye
Eyes and testes harvested from WT and Cd46/ mice were
placed in Tissue-Tek OCT optimal cutting temperature
compound (Sakura Finetek, Torrance, CA), snap-frozen, and
stored in sealed vials at 80C until sectioning by cryostat.
Tissue sections (8 mm thick) were ﬁxed in 95% ethanol and
5% glacial acetic acid (Thermo Fisher Scientiﬁc) for 20 mi-
nutes at20C. Sections were incubated in 1% bovine serum
albumin (Thermo Fisher Scientiﬁc) and 10% donkey serum
(Jackson ImmunoResearch Laboratories) for 30 minutes to
block nonspeciﬁc binding. Tissue sections were treated with
rabbit polyclonal anti-mouse CD46 Ab (dilution 1:400) for
18 hours at 4C. DyLight 549econjugated anti-rabbit IgG
(donkey) (dilution 1:400; Jackson ImmunoResearch Labo-
ratories) served as the secondary Ab.
To identify Müller cells in the retina and cells of mesen-
chymal origin in the testis, the sections were treated with rabbit
anti-vimentin monoclonal Ab conjugated with Alexa Fluor
488 (dilution 1:200; Cell Signaling Technology, Danvers,
MA). Mouse monoclonal antiecytokeratin 18 (antieCK-18)
primary Ab (ABR; Thermo Fisher Scientiﬁc), goat anti-mouse
Alexa Fluor 488econjugated secondary Ab (Life Technolo-
gies), and a M.O.M. (mouse-on-mouse) immunodetection kit
(Life Technologies) were used to identify RPE cells. Control
stains were performed with an isotype-matched Ab at a con-
centration equal to that of the primary Ab. Additional controls
included omitting the primary or secondary Ab. Anti-CD46
polyclonal Ab, blocked with excess recombinant CD46 pro-
tein (puriﬁed mouse CD46 CCPs 1 and 2 and mouse CD46
CCPs 3 and 4) was also used as control. Sections were
mounted in ProLong antifade reagent with DAPI (Life Tech-
nologies) and examined using an LSM510 laser confocal
microscope (Carl Zeiss Microscopy, Jena, Germany). Beam
splitters were set up as follows: 405 nm laser (10%) window
420 to 480 nm, 488 nm laser (10%) window 505 to 530 nm,
and 561 nm laser (15%) window 575 to 615 nm. Eight-bit
images were obtained using the microscope in sequential
mode with line average of 8 and a format of 1024  1024
pixels. We captured a single 1-mm optical slice of each section
using an EC Plan-Neoﬂuar 40/1.30 oil differential interfer-
ence contrast (DIC) objective or a Plan-Apochromat 63/1.4
oil DIC objective. All images were captured with the same
settings. DIC images were captured to facilitate localization of
histological structures of the eye. Cryosections from the eyes
were also stained with hematoxylin and eosin and investigated
using a Vanox-S microscope (Olympus, Tokyo, Japan)
equipped with a GO-5 camera (QImaging, Surrey, BC, Can-
ada). Images of hematoxylin and eosinestained sections were
captured using an SPlan 40/0.7 objective (Olympus).
MAC Deposition and VEGF Expression
Eyes harvested fromWTandCd46/micewereﬁxed in 10%
neutral buffered formalin (Sigma-Aldrich) for 4 hours at 25C.
Eyes were embedded in parafﬁn, and 5-mm sections were cut.
After deparafﬁnization in xylene and rehydration, sections2539
Figure 1 Generation of the Cd46/ mouse. A: Targeted homologous
recombination, as identiﬁed by Southern blot analysis of PvuII-digested
DNA samples extracted from ES cell clones. Two DNA fragments, WT 9.3
kb and targeted 6.6 kb, are identiﬁed by a probe with sequences from
CCP 2b to CCP 3 of the Cd46 gene. Positive ES clones (such as number 10)
were injected into C57BL/6J blastocysts to generate chimeric mice. B:
Genotype analysis of mouse tail DNA with Neo and CD46 primers. A com-
bination of these primers is capable of distinguishing WT, heterozygous,
and homozygous mice. C: Immunohistochemical staining of the epididymis
from WT and Cd46/ mice with rabbit anti-mouse CD46 Ab. CD46 protein
was detected in WT spermatozoa, but not in spermatozoa of the Cd46/
mice. CCP, complement control protein (repeat or module); WT, wild type.
Lyzogubov et alwere treated with antigen unmasking solution (Vector Labo-
ratories). All samples were processed at the same time. For
detection of the MAC, sections were treated with rabbit
polyclonal anti-MAC (C9 neoepitope) Ab (primary Ab), fol-
lowed byAlexa Fluor 594econjugated donkey anti-rabbit IgG
[(heavy chain and light chain) (secondary Ab) (Life Tech-
nologies). For VEGF staining, we used rabbit polyclonal anti-
VEGF (Abcam, Cambridge, MA) as the primary Ab and
Alexa Fluor 594econjugated goat anti-rabbit (Life Technol-
ogies) as the secondary Ab. Müller cells in the retina were
identiﬁed as described above.Mouse monoclonal antieCK-18
(primary Ab) (ABR; Thermo Fisher Scientiﬁc), goat anti-
mouse Alexa Fluor 488econjugated (secondary Ab) (Life
Technologies), and a M.O.M. immunodetection kit (Life
Technologies) was used to identify RPE cells. Sections were
examined with an LSM510 laser confocal microscope (Zeiss)
using settings as described above.
Induction and Measurement of CNV and VEGF
Expression in Laser Spots
CNV was induced by laser photocoagulation with an argon
laser (spot size, 50 mm; duration, 0.05 seconds; power, 260
mW) as described previously.16e23 Three laser spots were
placed in each eye, close to the optic disk. Production of a
vaporization bubble at the time of laser conﬁrmed the rupture of
Bruch’s membrane. Mice were anesthetized with a ketamine/
xylazine cocktail at days 2, 3, and 7 after laser treatment. They
were then perfused with 0.75 mL of phosphate-buffered saline
containing 50 mg/mL of ﬂuorescein isothiocyanateelabeled
dextran (2  106 molecular weight) (Sigma-Aldrich) before
sacriﬁce. The eyes were harvested and ﬁxed for 4 hours in 10%
neutral buffered formalin (Sigma-Aldrich), and RPEechor-
oidescleral ﬂat mounts were prepared.16e23 For VEGF stain-
ing, we used rabbit polyclonal anti-VEGF (Abcam, Cambridge,
MA) as the primary Ab and Alexa Fluor 594econjugated goat
anti-rabbit (Life Technologies) as the secondary Ab. The ﬂat
mounts were mounted in ProLong antifade reagent (Life
Technologies) with the sclera facing down and were examined
under an LSM510 confocal microscope (Zeiss). In confocal
micrographs, areas of green ﬂuorescence (CNV complex size)
or red ﬂuorescence (VEGFþ staining) in laser spots were
measured using NIH ImageJ software. Laser spots were iden-
tiﬁed by staining for ﬁlamentous actin using Alexa Fluor
647econjugated phalloidin (Life Technologies). If the CNV
was 3% of the total laser spot area, it was graded negative;
CNV of >3% was graded positive.
Ethics
The knockout mouse was generated under an animal pro-
tocol approved by the Division of Comparative Medicine at
Washington University in St. Louis. Animal experiments
were approved by the Institutional Animal Care and Use
Committee, University of Arkansas for Medical Sciences,
Little Rock.2540Statistical Analysis
Data were analyzed and compared using the U-test or
analysis of variance, and differences were considered sta-
tistically signiﬁcant at P < 0.05.
Results
Generation of the Cd46/ Mouse
To generate a CD46 knockout mouse, the Cd46 gene was
disrupted, as described under Materials and Methods. A
positive ES clone is shown in Figure 1A. PCR reactions of
mouse tail DNA were performed to distinguish the three
genotypes (Figure 1B). Analysis with a polyclonal anti-
mouse CD46 Ab was used to verify the absence of CD46
protein in the epididymis of the Cd46/ mice (Figure 1C).
These results demonstrated that inactivation of the mouse
Cd46 gene was complete. Homozygous Cd46/ mice were
viable, developed normally, and were fertile.
Expression of CD46 mRNA and Protein in the Posterior
Segment of the Mouse Eye
RT-PCR was used to detect CD46 mRNA in the retina and
choroid of eyes from WT and Cd46/ mice. Testes wereajp.amjpathol.org - The American Journal of Pathology
CD46 Protects against CNV in Miceharvested from WT mice to serve as a positive control.
Using RT-PCR, we detected CD46 mRNA in the eye and
testis of WT mice, which was absent in the eye and testis of
Cd46/ mice (Figure 2A). These ﬁndings establish a sec-
ond tissue site for the expression of CD46 in mouse.
The speciﬁc location of CD46 in the eye was assessed by
immunoﬂuorescence (IF) using rabbit polyclonal anti-
mouse CD46 Ab. In WT mice, an intense signal for CD46
was observed on the basolateral surface of RPE cells
(Figure 2, BeD) and, as expected, in the testis (Figure 2I).
RPE cells were identiﬁed by staining for the intermediate
ﬁlament protein CK-18 (Figure 2, B and D). Less intenseThe American Journal of Pathology - ajp.amjpathol.orgstaining was present in the choroid of WT mice (Figure 2, B
and C). No positive signal was detected in the same struc-
tures of WT mice stained using primary Ab blocked with
recombinant protein (Figure 2E), with the primary Ab
omitted, (Figure 2F), or stained with rabbit nonimmune
serum (Figure 2, G and J), and likewise no positive signal
was detected in Cd46/ mice (Figure 2, H and K).
Differential expression of CD46 was also observed in the
WT retina (Figure 3). Hematoxylin and eosinestained sec-
tions were used to demonstrate the choroid and layers of the
retina (Figure 3E). Moderate CD46 expression was observed
in the inner plexiform layer, outer plexiform layer, innerFigure 2 CD46 expression and localization in the
mouse eye. A: CD46 mRNA was analyzed in the retina
and the choroid of C57BL/6J (WT) and Cd46/mice.
Representative ethidium bromideestained gel shows
CD46 (230 bp) transcripts in the retina and choroid
(lane 4) and testis (lane 7) of WT mice. CD46 mRNA
was not detected in the eye (lane 3) or testis (lane 6)
of Cd46/ mice. b-Actin (330 bp) was used as a
loading control in the eye (lanes 3 and 4) and testis
(lanes 6 and 7) of WT and Cd46/mice. Size markers
(100 bp DNA ladder, lane 1). Lane 2, nuclease free
water; lane 5, without reverse transcriptase, and lane
8, empty. BeK: For IF analysis, frozen sections were
stained with rabbit polyclonal anti-CD46 Ab, CK-18, or
vimentin. DIC microscopy was used to identify ocular
structures on sections from WT mice. Nuclei were
counterstained with DAPI. Confocal micrographs
show staining for CD46 on the basolateral surface of
RPE cells (B, C, and D), in choroid (B and C), and in
testis (I) of WT mice. No staining was observed in the
negative controls stained using a primary Ab blocked
with recombinant protein (E), by omitting the pri-
mary Ab (F), or with rabbit nonimmune serum (G and
J), nor in Cd46/ mice (H and K). Results shown are
representative of ﬁve independent experiments. Scale
bars: 80 mm (IeK); 25 mm (B, C, and EeH); 10 mm
(D). RPE, retinal pigment epithelium; Vim, vimentin;
WT, wild type.
2541
Figure 3 CD46 expression in the mouse retina. A: Cd46/ mouse retina served as a negative control. E: Retinal layers and choroid (hematoxylin and
eosin). B, C, F, and G: Frozen sections of eyes from WT C57BL/6J mice were subjected to IF staining with rabbit polyclonal Abs to CD46 (B and F) and vimentin
(C and G). CD46þ signal (red) was detected in the neuronal retina and RPE (B and F). D and H: CD46 colocalized with vimentin. Within the neuronal retina, the
most intense staining was detected in the processes of vimentinþ (green) Müller cells in the OLM (D and H). I: Confocal micrographs were merged with DIC
images. Nuclei were counterstained with DAPI (blue). Images are representative of ﬁve independent experiments. Scale bars: 20 mm (AeE); 10 mm (FeI). GCL,
ganglion cell layer; ILM, inner limiting membrane; INL, inner nuclear layer; IPL, inner plexiform layer; IS, inner segment of photoreceptors; OLM, outer limiting
membrane; ONL, outer nuclear layer; OPL, outer plexiform layer; OS, outer segment of photoreceptors; RPE, retinal pigment epithelium; Vim, vimentin.
Lyzogubov et alsegment of photoreceptors, and outer segment of photore-
ceptors (Figure 3, B and F). Intense staining for CD46 was
noted in the outer limiting membrane (OLM) (Figure 3, B and
F). By contrast, the inner limiting membrane(ILM), ganglion
cell layer, inner nuclear layer, and outer nuclear layer were
negative for CD46 (Figure 3, B and F). Weak background
staining was observed in the retinal sections of Cd46/mice
(Figure 3A). Using IF analysis, we identiﬁed the intermediate
ﬁlament protein vimentin in radial processes of Müller cells
(Figure 3, C and G). CD46 colocalized with vimentinþ
Müller cells (Figure 3D), especially in the OLM (Figure 3H).
Thus, CD46 is expressed in multiple speciﬁc locations in the
mouse eye.
Role of CD46 in Laser-Induced CNV
In view of these results and previous ﬁndings of an important
role for complement activation in the development of laser-
induced CNV,16e18,20,21,23 we studied the response of the
Cd46/ mouse to laser injury. CNV was induced by
photocoagulation using an argon laser, and mice were
sacriﬁced at days 2, 3, and 7 after laser treatment. Confocal
analyses of RPEechoroidescleral ﬂat mounts revealed that2542Cd46/ mice were more susceptible to laser-induced CNV
than WT mice. For example, at day 2 after laser treatment,
19% of the laser spots were positive for CNV, compared with
0% in WT mice (Figure 4A). At day 3 after laser treatment,
42% of the laser spots had developed CNV in Cd46/mice,
compared with 11% in WT mice (Figure 4A), but CNV size
did not differ signiﬁcantly between groups (Figure 4, BeD).
All spots were positive for CNV at day 7 (Figure 4A), but
Cd46/mice had developed signiﬁcantly more severe CNV
(P < 0.05) (Figure 4, EeG).
We compared VEGF expression in laser spots at days 3
and 7 after laser treatment in Cd46/ and WT mice, using
IF analysis. We noted signiﬁcantly increased VEGFþ
staining in laser spots at day 3 (Figure 5, AeC) and at day 7
(Figure 5, DeF) after laser treatment in Cd46/ mice,
compared with WT mice (P < 0.05).
Underlying Mechanism Responsible for Increased
Susceptibility of the Cd46/ Mouse to CNV
This mouse model of CNV is dependent on complement acti-
vation. MAC deposition leads to the release of angiogenic
growth factors, including VEGF, that drive neovascularization.ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Effect of CD46 on the incidence of CNV and the size of CNV complex. A: CNV was induced in both eyes of C57BL/6J (WT; circles) and Cd46/ (squares)
mice by laser photocoagulation. Increased incidence of CNV was observed at days 2 and 3 after laser treatment in Cd46/ mice, compared with WT mice. BeG:
Representative confocal photomicrographs of RPEechoroidescleral ﬂat mounts with ﬂuorescein isothiocyanateedextran perfused vessels (green) fromWT (B and E)
and Cd46/ (C and F) mice, with cumulative data of CNV quantiﬁcation (D and G). At day 3 after laser treatment, the size of the CNV complex in Cd46/mice (C and
D) is not signiﬁcantly different from those in WT (B and D). However, at day 7 after laser treatment, the CNV complex is signiﬁcantly larger in Cd46/mice (F and G),
compared with WTmice (E and G). Data are expressed as means SEM, representative of two independent experiments. nZ 3 mice per group at each post-treatment
time point. *P < 0.05, analysis of variance. Scale barZ 100 mm. CNV, choroidal neovascularization; RPE, retinal pigment epithelium; WT, wild type.
CD46 Protects against CNV in MiceBecause the MAC formed as a result of complement activation
is essential for the expression and release of growth factors to
mediate the development of laser-induced CNV in the mouse
model,16e18 we performed experiments to compare the levels of
MAC and VEGF in the retina and the choroid of the Cd46/
and WT mice.MAC in the Retina and Choroid of the Cd46/ Mouse
Parafﬁn-embedded sections of eyes were stained with an
anti-mouse C9 Ab. This Ab recognizes a neoepitope in C9
that arises when C9 is part of the MAC. We observed weak
staining of the MAC in the retina (Figure 6B) and choroid
(Figure 6J) of WT mice. In Cd46/ mice, however, MAC
staining was more intense in both retina and choroid
(Figure 6, F and O). Increased MAC deposition on the inner
surface of the retina was observed, including strong coloc-
alization with vimentinþ ﬁbrillar structures in Cd46/ mice
(Figure 6, G and H), compared with WT mice (Figure 6, C
and D). We also observed increased deposition of MAC on
the basal surface of CK-18þ RPE cells in Cd46/ mice
(Figure 6, PeR), compared with WT mice (Figure 6, KeM).
No positive staining was detected in negative control section
(Figure 6, A, E, I, and N). Western blot analyses conﬁrmed
the IF results, demonstrating increased C9 levels in neuronal
retina, RPE, and choroid of Cd46/ mice (P < 0.05)
(Figure 6, SeU).The American Journal of Pathology - ajp.amjpathol.orgExpression of VEGF in the Retina and Choroid of the
Cd46/ Mouse
We performed IF and ELISA to assess VEGF expression in
mouse retina and choroid. Using IF on parafﬁn-embedded
sections, we observed VEGF expression in untreated WT
mice in vimentinþ Müller cells, other retinal cells sur-
rounding Müller cells (Figure 7, BeD), and CK-18þ RPE
cells (Figure 7, JeM). In untreated Cd46/ mice, expres-
sion was more intense in vimentinþ Müller cells (Figure 7,
FeH) and in CK-18þ RPE cells (Figure 7, OeR). IF per-
formed without the primary Ab demonstrated no signiﬁcant
staining (Figure 7, A, E, I, and N). Levels of VEGF protein,
as determined by ELISA, were also signiﬁcantly elevated in
the neuronal retina, RPE, and choroid harvested from the
eyes of untreated Cd46/, compared with untreated WT
mice (P < 0.05) (Figure 7S).Discussion
Studies performed in humans and in mice, particularly over
the past decade, have substantially improved our under-
standing of the role of the complement system in
AMD.11e24 Complement inhibitors expressed in the retina
and choroid provide cellular protection during intraocular
engagement of this innate immune cascade.11e24 A decrease
in this regulatory activity, for which there is strong genetic2543
Figure 5 Effect of CD46 on VEGF expression in laser spots. AeF: CNV was induced in C57BL/6J (WT) and Cd46/ mice by laser photocoagulation. Mice
were sacriﬁced at days 3 and 7 after laser treatment. Representative confocal photomicrographs of RPEechoroidescleral ﬂat mounts with VEGFþ staining (red)
from WT (A and D) and Cd46/ (B and E) mice, with cumulative data of VEGF quantiﬁcation (C and F). Laser-injured areas (red) in laser spots were measured
using NIH ImageJ software, At both day 3 (C) and day 7 (F) after laser treatment, the VEGFþ area was signiﬁcantly higher in Cd46/ mice, compared with WT
controls. Data are expressed as means  SEM, representative of two independent experiments. n Z 3 mice per group at each post-treatment time point.
*P < 0.05. Scale bar Z 100 mm. RPE, retinal pigment epithelium; WT, wild type.
Lyzogubov et alevidence in humans, leads to excessive activation of the
alternative complement pathway and thereby contributes to
the pathology of AMD. In animal models, excessive MAC
formation within the retina causes an increase in production
of angiogenic growth factors that drive the development of
CNV.16e18 With the present study, we have demonstrated
the expression of CD46 in multiple segments of the mouse
eye and, using a Cd46/ mouse model, we have elucidated
how CD46 deﬁciency predisposes to more severe CNV in a
laser injury model.
In humans and most other mammals, CD46 is a widely
expressed membrane regulator that inhibits the alternative
pathway on the same cell on which it is expressed
(intrinsic protection).26,27 CD46 accomplishes this by
serving as a cofactor protein for the plasma serine protease
factor I. By limited and speciﬁc proteolysis, factor I
cleaves C3b bound to CD46 on a host cell. The resulting
iC3b fragment cannot engage the highly efﬁcient feedback2544loop of the alternative pathway,26,27 and thus the activation
process is curtailed.
The expression of CD46 in multiple locations in the
human eye is well documented.28e31 In 2003, using human
donor eyes, primary cultures of human RPE, and ARPE-19
cells, we demonstrated that CD46 is preferentially localized
to the basolateral surface of the RPE.30 Other researchers
have also described CD46 staining in this location in human
donor eyes.31,39,40 In mouse and rat, however, CD46 was
initially reported to be expressed solely on the inner acro-
somal membrane of spermatozoa, where it is also expressed
in humans.32,41 Complement receptor 1-related gene/
protein-y (Crry) was hypothesized to substitute for the
widely expressed CD46 in all other locations in the
mouse,42 because it is widely expressed and possesses
cofactor activity for mouse C3b.
In the present study, we observed that CD46 is expressed
in the retina, RPE, and choroid of the mouse eye. Twoajp.amjpathol.org - The American Journal of Pathology
Figure 6 The MAC of complement is increased in the retina and choroid of the Cd46/ mouse. Untreated (nonlasered) mice were used. AeR: Repre-
sentative confocal photo micrographs of MAC staining (red), vimentin staining (green), and CK-18 staining (green) in parafﬁn-embedded sections of WT
C57BL/6J neuronal retina (AeD) and RPEechoroid (IeM) and of Cd46/ neuronal retina (EeH) and RPEechoroid (NeR). In DIC merged images (M and R),
nuclei are stained with DAPI (blue). MAC staining was more intense in the retina and choroid of Cd46/ mice (F and O), compared with WT mice (B and J).
Increased MAC deposition was observed on the inner surface of the retina, including vimentinþ Müller cells (H), and on the basal surface of CK-18þ RPE cells (Q
and R) of Cd46/ mice, compared with WT mice (D, L, and M). Control sections were stained without the primary Ab (negative control) (A, E, I, and N). S and
T: Representative Western blot analyses of MAC (approximately 70 kDa) and b-actin (approximately 42 kDa) in retina and choroid of WT (lane 3) and Cd46/
(lane 5) mice. Lane 1, molecular weight marker; lanes 2 and 3, empty. Blots for MAC and b-actin were performed separately with an equivalent amount of
protein loaded. U: Densitometric analysis of blots is expressed as the ratio of the intensity of the MAC protein to the intensity of b-actin protein band. Data are
expressed as means  SEM. Results are representative of four (AeR) or 7 (SeU) independent experiments. *P < 0.05. Scale barZ 40 mm. Ch, choroid. Ab,
antibody; MAC, membrane attack complex; RPE, retinal pigment epithelium; WT, wild type.
CD46 Protects against CNV in Micerecent prior reports of CD46 expression in the mouse eye do
not agree on which cell types express CD46,43,44 and in one
of those studies CD46 expression was not observed in WT
mice.44 Mallam et al,43 using immunohistochemistry and a
commercially available monoclonal Ab raised to human
CD46, found that CD46 is expressed in the inner and the
outer segments of photoreceptors of C57BL/6J mice; how-
ever, expression at the OLM of the neurosensory retina or
basolaterally on the RPE or in the choroid was not found.
Ambati et al,44 using immunohistochemistry and a commer-
cially available rabbit polyclonal Ab raised to human CD46,
observed reactivity in the eyes of aged Ccl2/ and Ccr2/The American Journal of Pathology - ajp.amjpathol.orgmice, but not in age-matched WT C57BL/6J mice. We,
however, have been unable to detect speciﬁc staining in the
mouse eye or spermatozoa, using these two Abs (unpublished
data). In the present study, using a polyclonal Ab raised to
mouse CD46, we observed speciﬁc basolateral membrane
staining of the RPE, as well as CD46 expression in the retina
and the choroid of WT mice. To summarize, the differences
between the present study and the two other studies are likely
attributable to the fact that we used an Ab directed against
mouse CD46, rather than commercially available anti-CD46
Abs raised to human CD46. Furthermore, to validate our re-
sults, we had the considerable advantage of the availability of2545
Figure 7 VEGF is increased in the retina and the choroid of Cd46/ mice. Untreated (nonlasered) Cd46/
and WT mice were used. AeR: Representative separate or merged confocal photomicrographs of parafﬁn-
embedded sections of WT C57BL/6J mouse neuronal retina (AeD) and RPEechoroid (IeM), and of Cd46/
mouse neuronal retina (EeH) and RPEechoroid (NeR) stained for VEGF (red) (B, F, J, and O), vimentin (green)
(C andG), or CK-18 (green) (K and P). Nuclei were counterstained with DAPI. The VEGF signal wasmore intense in
the retina and choroid of Cd46/ mice (F and O), compared with WT mice (B and J). Increased VEGF expression
was detected in the ganglion cell layer, including vimentinþMüller cells (H), and in CK-18þ RPE cells (Q and R) in
Cd46/ mice, compared with WT mice (D, L, and M). Control sections were stained without the primary Ab
(negative control) (A, E, I, andN).S:Protein-speciﬁc ELISA analysis of VEGF protein levels in neuronal retina, RPE,
and choroid revealed signiﬁcantly increased VEGF levels in Cd46/ mice, compared with WT mice. Images are
representative of three independent experiments. Data are expressed asmeans SEM. nZ 11 samples (duplicate
determinations) per group. *P< 0.05. Scale barZ 40 mm. Ab, antibody; ELISA, enzyme-linked immunosorbent
assay; RPE, retinal pigment epithelium; VEGF, vascular endothelial growth factor; WT, wild type.
Lyzogubov et althe Cd46/ mouse as a negative control, and we routinely
used mouse testis as a positive control.
The expression pattern for CD46 in the mouse eye is of
interest. The most intense staining was on the basolateral
surface of RPE cells (as it is in humans14,30,31,39,40) and on the
OLM. Also, moderate CD46 staining was present in both the
inner plexiform layer and outer plexiform layer. Although it
is possible that CD46 immunoreactivity at the OLM may
represent accumulation of soluble CD46,11,12,29 similar to
that seen with albumin,45 this staining pattern in the retina is,
in our opinion, most consistent with CD46 localization on
Müller cells, especially at terminal OLM processes. We have
previously reported that the soluble form of CD46 is present
in normal human vitreous.29 Thus, the expression (or accu-
mulation) of CD46 is polarized toward the OLM end of the
Müller cells, because no staining is present at the ILM.
Staining for CD46 in human neuronal retina is reported in the2546outer segment and inner segment of photoreceptors28 and
retinal vessels.46 Elucidation of the nature of the variable and
lighter staining pattern in choroid requires further study.
A role for CD46 in CNV was explored using Cd46/
mice in a model of laser-induced CNV. The Cd46/ mice
had increased expression of VEGF in laser spots, compared
with WT mice, and developed a more severe clinical pheno-
type of CNV. Recent studies analyzing CD46 expression in
human eyes with the dry form of AMD indicate that CD46 is
present in RPE cells overlying drusen.14 Furthermore, in the
eyes of patients with early AMD, CD46 staining was mark-
edly reduced in RPE cells.21,42 Those reports suggest that
decreased expression of CD46 in dry AMD contributes to
disease pathogenesis. Our present ﬁndings indicate that a
deﬁciency of CD46 exacerbates CNV in mouse.
To determine why the Cd46/ mouse is more prone
to CNV, we analyzed MAC and VEGF levels. We haveajp.amjpathol.org - The American Journal of Pathology
CD46 Protects against CNV in Micepreviously reported that, in laser-induced CNV, MAC
deposition is a major mediator of the disease process, having
a direct effect on VEGF production.16e18 Additionally, there
is ample evidence in the literature that VEGF is a key
angiogenic growth factor in the development of CNV, both in
humans with wet AMD47e49 and in animal models of
CNV.16e23 Our present results indicate that the MAC and
VEGF are present in signiﬁcantly higher amounts in the
neuronal retina, RPE, and choroid of the Cd46/ mouse.
Furthermore, increased VEGF expression in Müller cells and
in RPE overlapped the sites featuring elevated MAC depo-
sition. This was prominent at the ILM as well, although our
present results did not demonstrate CD46 expression in this
region. We have several hypotheses about this ﬁnding, all of
which would require further investigation. Either soluble
CD46 present in the vitreous humor or soluble CD46
migrating through the retina from the RPE may be protective
at the ILM.We even consider it possible that CD46 present at
the OLM region of the Müller cells is normally protective at
the ILM and in the vitreous, because it is possible that OLM
membrane-bound CD46 helps to maintain tight junctions at
this critical barrier through local mitigation of inﬂammatory
factors. Absence of CD46 allows the MAC to migrate to the
ILM and vitreous through a leaky barrier. This process could
in turn likely up-regulate VEGF in a manner not seen in WT
mice. Thus, there is an intriguing relationship among CD46
expression, MAC deposition, and elevated VEGF levels that
translates into a more severe form of laser-induced CNV. We
suggest that, in mice, CD46 has a role in the initiation and the
progression of choroidal angiogenesis.
In conclusion, here we have reported several novel ob-
servations: i) CD46, the major membrane regulator of the
human alternative pathway, is also expressed in the mouse
retina, RPE, and choroid; ii) baseline levels of MAC and
VEGF are increased in the retina and the choroid of mice
deﬁcient in CD46, suggesting an elevated, spontaneous
basal level of complement turnover; and iii) the Cd46/
mouse develops more severe CNV in the laser model. Taken
together, these ﬁndings raise the possibility that inhibition of
the alternative pathway of the complement system (eg, by
recombinant CD46) could be a successful therapeutic
strategy for treatment of AMD.
Acknowledgments
We thank Kathryn Liszewski for helpful suggestions and
Madonna Bogacki and Lorraine Schwartz for expert secre-
tarial assistance.
References
1. Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de
Jong PT, Nemesure B, Mitchell P, Kempen J; Eye Diseases Prevalence
Research Group: Prevalence of age-related macular degeneration in the
United States [Erratum appeared in Arch Ophthalmol 2011, 129:1188].
Arch Ophthalmol 2004, 122:564e572The American Journal of Pathology - ajp.amjpathol.org2. Coleman HR, Chan CC, Ferris FL 3rd, Chew EY: Age-related macular
degeneration. Lancet 2008, 372:1835e1845
3. Gehrs KM, Anderson DH, Johnson LV, Hageman GS: Age-related
macular degenerationeemerging pathogenetic and therapeutic con-
cepts. Ann Med 2006, 38:450e471
4. Christoforidis JB, Tecce N, Dell’Omo R, Mastropasqua R,
Verolino M, Costagliola C: Age related macular degeneration and
visual disability. Curr Drug Targets 2011, 12:221e233
5. Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB,
Saaddine J; Vision Health Cost-Effectiveness Study Group: Fore-
casting age-related macular degeneration through the year 2050: the
potential impact of new treatments. Arch Ophthalmol 2009, 127:
533e540
6. Husain D, Ambati B, Adamis AP, Miller JW: Mechanisms of age-
related macular degeneration. Ophthalmol Clin North Am 2002, 15:
87e91
7. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BEK,
Hofman A, Jensen S, Wang JJ, de Jong PT: Risk factors for age-related
macular degeneration: pooled ﬁndings from three continents.
Ophthalmology 2001, 108:697e704
8. Evans JR: Risk factors for age-related macular degeneration. Prog
Retin Eye Res 2001, 20:227e253
9. Khandhadia S, Cherry J, Lotery AJ: Age-related macular degeneration.
Adv Exp Med Biol 2012, 724:15e36
10. Yates JR, Moore AT: Genetic susceptibility to age related macular
degeneration. J Med Genet 2000, 37:83e87
11. Bora NS, Jha P, Lyzogubov VV, Bora PS: Emerging role of com-
plement in ocular diseases. Curr Immunol Rev 2011, 7:360e367
12. Bora NS, Jha P, Bora PS: The role of complement in ocular pathology.
Semin Immunopathol 2008, 30:85e95
13. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT,
Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA,
Rickman CB, Bok D, Hageman GS, Johnson LV: The pivotal role of
the complement system in aging and age-related macular degeneration:
hypothesis re-visited. Prog Retin Eye Res 2010, 29:95e112
14. Johnson LV, Leitner WP, Staples MK, Anderson DH: Complement
activation and inﬂammatory processes in drusen formation and age
related macular degeneration. Exp Eye Res 2001, 73:887e896
15. Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S,
Goldstein JI, Triebwasser M, Anderson HE, Zerbib J, Kavanagh D,
Souied E, Katsanis N, Daly MJ, Atkinson JP, Raychaudhuri S: Rare
variants in CFI, C3 and C9 are associated with high risk of
advanced age-related macular degeneration. Nat Genet 2013, 45:
1366e1370
16. Bora PS, Sohn JH, Cruz JM, Jha P, Nishihori H, Wang Y, Kaliappan S,
Kaplan HJ, Bora NS: Role of complement and complement membrane
attack complex in laser-induced choroidal neovascularization. J
Immunol 2005, 174:491e497
17. Bora NS, Kaliappan S, Jha P, Cu Q, Sohn JH, Dhaulakhandi DB,
Kaplan HJ, Bora PS: Complement activation via alternative pathway is
critical in the development of laser-induced choroidal neovascularization:
role of factor B and factor H. J Immunol 2006, 177:1872e1878
18. Bora NS, Kaliappan S, Jha P, Xu Q, Sivasankar B, Harris CL,
Morgan BP, Bora PS: CD59, a complement regulatory protein, con-
trols choroidal neovascularization in a mouse model of wet-type age-
related macular degeneration. J Immunol 2007, 178:1783e1790
19. Kaliappan S, Jha P, Lyzogubov VV, Tytarenko RG, Bora NS,
Bora PS: Alcohol and nicotine consumption exacerbates choroidal
neovascularization by modulating the regulation of complement sys-
tem. FEBS Lett 2008, 582:3451e3458
20. Bora NS, Jha P, Lyzogubov VV, Kaliappan S, Liu J, Tytarenko RG,
Fraser DA, Morgan BP, Bora PS: Recombinant membrane-targeted
form of CD59 inhibits the growth of choroidal neovascular complex
in mice. J Biol Chem 2010, 285:33826e33833
21. Lyzogubov VV, Tytarenko RG, Jha P, Liu J, Bora NS, Bora PS: Role
of ocular complement factor H in a murine model of choroidal neo-
vascularization. Am J Pathol 2010, 177:1870e18802547
Lyzogubov et al22. Lyzogubov VV, Tytarenko RG, Liu J, Bora NS, Bora PS: Polyethylene
glycol (PEG)-induced mouse model of choroidal neovascularization. J
Biol Chem 2011, 286:16229e16237
23. Liu J, Jha P, Lyzogubov VV, Tytarenko RG, Bora NS, Bora PS:
Relationship between complement membrane attack complex, che-
mokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth
factor in mouse model of laser-induced choroidal neovascularization. J
Biol Chem 2011, 286:20991e21001
24. Liszewski MK, Atkinson JP: Regulatory proteins of complement.
Edited by Volanakis J, Frank M. The Human Complement System in
Health and Disease. New York, Marcel Dekker, 1998, pp 149e166
25. Morgan BP, Harris CL: Regulation in the complement system. Com-
plement Regulatory Proteins. San Diego, Academic Press, 1999, pp
32e38
26. Liszewski MK, Leung M, Cui W, Subramanian VB, Parkinson J,
Barlow PN, Manchester M, Atkinson JP: Dissecting sites important for
complement regulatory activity in membrane cofactor protein (MCP;
CD46). J Biol Chem 2000, 275:37692e37701
27. Liszewski MK, Kemper C, Price JD, Atkinson JP: Emerging roles and
new functions of CD46. Springer Semin Immunopathol 2005, 27:
345e358
28. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ: Dif-
ferential expression of the complement regulatory proteins in the
human eye. Invest Ophthalmol Vis Sci 1993, 34:3579e3584
29. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS: Complement regu-
latory activity of normal human intraocular ﬂuid is mediated by MCP,
DAF, and CD59. Invest Ophthalmol Vis Sci 2000, 41:4195e4202
30. McLaughlin BJ, Fan W, Zheng JJ, Cai H, Del Priore LV, Bora NS,
Kaplan HJ: Novel role for a complement regulatory protein (CD46) in
retinal pigment epithelial adhesion. Invest Ophthalmol Vis Sci 2003,
44:3669e3674
31. Fett AL, Hermann MM, Muether PS, Kirchhof B, Fauser S: Immu-
nohistochemical localization of complement regulatory proteins in the
human retina. Histol Histopathol 2012, 27:357e364
32. Riley-Vargas RC, Lanzendorf S, Atkinson JP: Targeted and restricted
complement activation on acrosome-reacted spermatozoa. J Clin Invest
2005, 115:1241e1249
33. Riley-Vargas RC, Atkinson JP: Expression of membrane cofactor
protein (MCP; CD46) on spermatozoa: just a complement inhibitor?
Mod Asp Immunobiol 2003, 3:75e78
34. Riley RC, Kemper C, Leung M, Atkinson JP: Characterization of
human membrane cofactor protein (MCP; CD46) on spermatozoa. Mol
Reprod Dev 2002, 62:534e546
35. Ryan SJ: Subretinal neovascularization. Natural history of an experi-
mental model. Arch Ophthalmol 1982, 100:1804e1809
36. Campochiaro PA: Retinal and choroidal neovascularization. J Cell
Physiol 2000, 184:301e310254837. Hogan B, Beddington R, Costantini F, Lacy E: Manipulating the
Mouse Embryo: A Laboratory Manual. ed 2. Cold Spring Harbor, NY,
Cold Spring Harbor Laboratory Press, 1994
38. Liszewski MK, Bertram P, Leung MK, Hauhart R, Zhang L,
Atkinson JP: Smallpox inhibitor of complement enzymes (SPICE):
regulation of complement activation on cells and mechanism of its
cellular attachment. J Immunol 2008, 181:4199e4207
39. Vogt SD, Barnum SR, Curcio CA, Read RW: Distribution of com-
plement anaphylatoxin receptors and membrane-bound regulators in
normal human retina. Exp Eye Res 2006, 83:834e840
40. Ebrahimi KB, Fijalkowski N, Cano M, Handa JT: Decreased membrane
complement regulators in the retinal pigmented epithelium contributes
to age-related macular degeneration. J Pathol 2013, 229:729e742
41. Tsujimura A, Shida K, Kitamura M, Nomura M, Takeda J, Tanaka H,
Matsumoto M, Matsumiya K, Okuyama A, Nishimune Y, Okabe M,
Seya T: Molecular cloning of a murine homologue of membrane
cofactor protein (CD46): preferential expression in testicular germ
cells. Biochem J 1998, 330:163e168
42. Kim YU, Kinoshita T, Molina H, Hourcade D, Seya T, Wagner LM,
Holers VM: Mouse complement regulatory protein Crry/p65 uses the
speciﬁc mechanisms of both human decay-accelerating factor and
membrane cofactor protein. J Exp Med 1995, 181:151e159
43. Mallam JN, Hurwitz MY, Mahoney T, Chévez-Barrios P, Hurwitz RL:
Efﬁcient gene transfer into retinal cells using adenoviral vectors:
dependence on receptor expression. Invest Ophthalmol Vis Sci 2004,
45:1680e1687
44. Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, Kuziel WA,
Rollins BJ, Ambati BK: An animal model of age-related macular
degeneration in senescent Ccl-2- or Ccr-2-deﬁcient mice. Nat Med
2003, 9:1390e1397
45. Vinores SA, Campochiaro PA, Lee A, McGehee R, Gadegbeku C,
Green WR: Localization of blood-retinal barrier breakdown in human
pathologic specimens by immunohistochemical staining for albumin.
Lab Invest 1990, 62:742e750
46. Zhang J, Gerhardinger C, Lorenzi M: Early complement activation and
decreased levels of glycosylphosphatidylinositol-anchored comple-
ment inhibitors in human and experimental diabetic retinopathy. Dia-
betes 2002, 51:3499e3504
47. Campa C, Harding SP: Anti-VEGF compounds in the treatment of
neovascular age related macular degeneration. Curr Drug Targets
2011, 12:173e181
48. Kim SJ, Toma HS, Barnett JM, Penn JS: Ketorolac inhibits choroidal
neovascularization by suppression of retinal VEGF. Exp Eye Res
2010, 91:537e543
49. Couch SM, Bakri SJ: Review of combination therapies for neovascular
age-related macular degeneration. Semin Ophthalmol 2011, 26:
114e120ajp.amjpathol.org - The American Journal of Pathology
